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Ultrasound lung comets in systemic sclerosis: a chest sonography
hallmark of pulmonary interstitial fibrosis
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Objective. To assess the correlation between ultrasound lung comets (ULCs, a recently described echographic sign of interstitial lung
fibrosis) and the current undisputed gold-standard high-resolution CT (HRCT) to detect pulmonary fibrosis in patients with SSc.
Methods. We enrolled 33 consecutive SSc patients (mean age 54 13 years, 30 females) in the Rheumatology Clinic of the University of Pisa.
We assessed ULCs and chest HRCT within 1 week independently in all the patients. ULC score was obtained by summing the number of lung
comets on the anterior and posterior chest. Pulmonary fibrosis was quantified by HRCT with a previously described 30-point Warrick score.
Results. Presence of ULCs (defined as a total number more than 10) was observed in 17 (51%) SSc patients. Mean ULC score was 37 50,
higher in the diffuse than in the limited form (73 66 vs 21 35; P< 0.05). A significant positive linear correlation was found between ULCs
and Warrick scores (r¼ 0.72; P< 0.001).
Conclusions. ULCs are often found in SSc, are more frequent in the diffuse than the limited form and are reasonably well correlated with
HRCT-derived assessment of lung fibrosis. They represent a simple, bedside, radiation-free hallmark of pulmonary fibrosis of potential
diagnostic and prognostic value.
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Introduction
Pulmonary fibrosis is a common manifestation in SSc and is the
second cause of death after cardiac involvement and pulmonary
hypertension [1]. High-resolution CT (HRCT) of the chest has
been found to be a sensitive and reproducible method to assess
the extent and the pattern of pulmonary fibrosis [2, 3]. The HRCT
signs of SSc are well documented, the main findings being a fine
reticular pattern involving the subpleural regions of the lower
lobe. Other common findings include ground-glass opacities,
honeycombing and parenchymal micronodules [4]. Chest HRCT
is presently considered as the diagnostic gold standard to assess
pulmonary fibrosis [5].
The lung has always been considered poorly accessible to ultra-
sound, as air prevents the progression of the ultrasound beam [6].
This is true in a normal, aerated lung, but the presence in the lung
of other structures besides air, opens the pulmonary acoustic
window and allows one to gain an insight into pulmonary
oedema and fibrosis that can be directly imaged and quantified.
‘Ultrasound lung comets’ (ULCs) are an echographic image
detectable with chest sonography [7]. This image consists of
multiple comet tails fanning out from the lung surface. They ori-
ginate from water-thickened or fibrosis-thickened interlobular
septa: the latter has been found in different forms of interstitial
lung disease (ILD), i.e. pulmonary fibrosis and sarcoidosis [8].
The present study hypothesis was that chest ultrasound detection
of ULCs may provide a feasible and accurate non-ionizing bedside
estimation of fibrosis involvement in patients with SSc, compared
with the diagnostic gold standard of chest HRCT.
Methods
Patient population
From May 2006 to March 2008, 33 consecutive patients (mean
age 54 13 years, 30 females) admitted to the Rheumatology
Clinic of the University of Pisa were included in the study. The
inclusion criteria were (i) previous diagnosis of SSc according to
the ACR classification criteria for SSc [9] and (ii) chest sonogra-
phy for specific assessment of ULCs, performed within a week of a
clinically driven HRCT. All examinations were read by indepen-
dent operators, unaware of the results of the other test. In all
patients, a modified Rodnan skin score was assessed, as previously
described [10].
The review board of the institute approved the study, and
written informed consent was obtained from the patients. All
patients gave their oral informed consent to undergo chest
sonography.
Pulmonary function tests
Standard spirometry and lung volume measurements were per-
formed in all patients by means of a fully equipped computerized
spirometric system (CPL Morgan Transflow Test PFT System,
Morgan Scientific, Haverhill, MA). Single-breath diffusing capa-
city for carbon monoxide (DLCO) was also measured. Actual
DLCO values were corrected for haemoglobin and CO levels. The
results were expressed as a percentage of predicted values [11, 12].
Chest sonography
Commercially available echographic equipment with a
2.5–3.5MHz cardiac sector transducer (2.5 cm long) was used
[Optigo, HP Sonos 7500 and IE33 (Philips Medical Systems,
Andover, MA, USA), Famiglia Mylab25 (Esaote, Genoa,
Italy)]. The investigators were unaware of chest HRCT results
and clinical data of the patients. The echographic examinations
were performed with patients in the supine or near-supine position
for the anterior scanning, and in the sitting position for the dorsal
scanning. Ultrasound examination was obtained moving the
probe longitudinally along anatomical reference lines, as pre-
viously described for the anterior chest [13] (Fig. 1A), whereas
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for the posterior chest, the ultrasound examination was obtained
by scanning along the paravertebral, scapular and posterior
axillary lines (Fig. 1B). The ULC sign was defined as an echo-
genic, coherent, wedge-shaped signal with a narrow origin in the
near field of the image [7]. In each intercostal space, the number of
ULCs was recorded. The sum of ULCs yielded a score denoting
the extent of pulmonary fibrosis diffusion. Presence of ULCs was
defined by a total number of ULCs more than 10, considering all
scanning sites on anterior and posterior chest. Zero was defined as
a complete absence of ULCs in all scanning sites. The full white
screen in a single scanning site was considered as corresponding to
10 ULCs. Two different observers (L.G. and F.F.), with dedicated
training and previous experience in joint reading, acquired and
analysed all chest sonography studies. Both readers were blinded
to chest HRCT results and clinical data. The intra- and inter-
observer variability of ULCs assessment is 5.1 and 7.4%,
respectively, in our laboratory [13].
Chest HRCT
CT examinations were performed on a spiral CT/I Highspeed
GEMs (General Electrics Medical Systems) scanner with one
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FIG. 1. (A) The pre-defined scanning sites on the anterior chest. Modified from Ref. [13] with kind permission from the American Journal of Cardiology. (B) The pre-defined
scanning sites on the posterior chest.
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row of detectors and a 1-s rotation time. All patients underwent
an A-P and L-L scout. After this, 35–55 scans were acquired at the
end of inspiration, in apnoea, from the apex to the lung base,
either in supine or in prone decubitus. The acquisition parameters
were as follows: sequential mode, 1-mm collimation and 10-mm
interval, 180–260mA average tube current (it depended on the
build of patient) and 120–140 kV tube voltage. A bone plus recon-
struction with lung window was used. No intravenous contrast
material was administered. The duration of the CT acquisition
was 35–45 s. Matrix was 512 512. Absorbed dose was in the
range 5–7mSv. Pulmonary involvement was evaluated by
topographically dividing the lung into segments, using the score
proposed by Warrick et al. [14] as previously described (Table 1).
This index includes a ‘severity score’, ranging from 0 (normal) to
15 (all lesions present), and an ‘extension score’, ranging from
0 (normal) to 15 (more than nine pulmonary segments involved).
A total Warrick score was obtained by summing the severity and
the extension scores.
Statistical analysis
Continuous variables are expressed as mean S.D. Categorical
variables are presented as counts and percentages. Univariate
comparisons were made with 2 or two-sample t-tests, as
appropriate. Correlation between parameters was assessed with
non-parametric Spearman correlation coefficient analysis or
with Pearson correlation, as appropriate. A P-value of <0.05
was considered as statistically significant. All statistical analyses
were performed using the SPSS/PC software package version
13 (SPSS, Chicago, IL, USA).
Results
Chest sonography examination was performed in all patients, and
feasibility was 100%. The time needed for chest scan and analysis
was always <10min. Chest sonography was performed by
Optigo in 17 (52%) patients, by HP Sonos 7500 in 7 (21%), by
IE33 in 6 (18%) and by Famiglia Mylab25 in 3 (9%). ULCs were
absent (less than 10) in 16 patients and present (more than 10) in
17. The clinical, spirometric and immunological features of the 33
patients, separated on the basis of ULC presence, are reported in
Table 2. A significant positive linear correlation was found
between echographic ULC score and Warrick score (r¼ 0.72;
P< 0.001; Fig. 2), with good concordance at individual patient
analysis between CT and chest sonography patterns of normal,
mildly fibrotic and severely fibrotic lung (Fig. 3). ULCs were
higher in the diffuse than in the limited form (73 66 vs
21 35; P< 0.05). We found a significant correlation between
ULC number and values of DLCO (r¼0.60; P< 0.05).
Discussion
ULCs observed with chest sonography are correlated with
presence and severity of pulmonary fibrosis as assessed by chest
HRCT in patients with SSc.
Biophysical mechanism of fibrotic ULCs
As previously discussed in detail [7, 15], ULCs are generated by
the reflection of the ultrasound beam from thickened subpleural
interlobular septa. In patients with heart failure, interlobular septa
are thickened by water, and ULCs represent an early sign of
pulmonary interstitial oedema, well related to the increase in
cardiac peptides [16], radiographic signs of pulmonary congestion
[13], invasive measurement of extravascular lung water and
pulmonary capillary wedge pressure [17]. In pulmonary fibrosis,
TABLE 1. Warrick score, as previously described [14]
Severity score
Parenchymal alteration
Ground glass opacities 1
Irregular pleural margins 2
Septal/subpleural lines 3
Honeycombing 4
Subpleural cysts 5
No. of lung segments
1–3 1
4–9 2
>9 3
Table adapted from Ref. [14] with kind permission from the Journal of Rheumatology.
TABLE 2. Clinical and immunological features
Characteristics ULCs absent (less than 10), n¼ 16 ULC present (more than 10), n¼17 P-value
Age, mean S.D., years 5513 5314 0.74
Female, n (%) 14 (87) 15 (94) 0.89
Duration of disease, mean S.D., years 45 87 0.15
Former or current smokers, n (%) 3 (19) 2 (12) 0.78
Diffuse form of the disease, n (%) 3 (19) 7 (41) 0.26
Skin score, mean S.D. 5.4 8.1 8.38.4 0.33
ANA, n (%) 4 (25) 4 (23) 0.92
ACA, n (%) 8 (50) 6 (35) 0.72
Scl-70, n (%) 4 (25) 5 (29) 0.70
TLC, mean S.D. 9721 8219 <0.05
VC, mean S.D. 11227 8530 <0.05
DLCO, mean S.D. 8322 6622 <0.05
ULCs, mean S.D. 33 6952 <0.001
Warrick score, mean S.D. 1.6 2.5 6.94.1 <0.001
Scl-70: anti-topoisomerase autoantibodies; TLC: total lung capacity; VC: vital capacity.
n = 33 
r = 0.72 
P < 0.001 
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FIG. 2. Correlation between ULC number and Warrick score in identifying
pulmonary interstitial fibrosis.
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interstitial lobular septa are thickened by collagen tissue accumu-
lation and, therefore, ULCs are generated by the same anatomical
interface as in heart failure, i.e. a thickened subpleural interlobular
septa, although the physical scatterers are represented by lung air
fibrosis and not by air–water impedance mismatch (Fig. 4).
Clinical implications
Detection, characterization and quantification of lung changes in
patients with SSc are important for several reasons. First, it may
help to identify early changes in asymptomatic patients establish-
ing the need of follow-up and treatment [18]; secondly, it may
have an important prognostic significance [4, 19]; finally, it can
provide support when monitoring lung disease progression in a
single patient with or without therapy [20]. Actually, HRCT is the
gold-standard technique for assessing pulmonary fibrosis in these
patients, also able to detect early stages of the disease [21, 22]. For
such reasons, these patients underwent HRCT scans annually.
According to the present study, chest sonography has the poten-
tial to identify and quantify pulmonary fibrosis accumulation, as
assessed by CT. The clinical impact of this information is magni-
fied by the low cost of this method, which can also be performed
at the bedside with a hand-held device, its very easy
acquisition, learning and interpretation of curves [23] and its
quick performing time (<10min for a total chest assessment).
Moreover, the technique is non-ionizing, and chest sonography
can easily be coupled with standard echocardiography, that
evaluates the other major prognostic determinant in these
patients, i.e. pulmonary hypertension [4]. Obviously, chest
HRCT remains the gold-standard technique for assessing pulmon-
ary fibrosis, also because it is the only tool that allows the evalua-
tion of the whole lung, and not only the subpleural interstitial
lobular septa. Nevertheless, ULCs can be useful to support CT,
especially for the follow-up of SSc patients during treatment, and
to reduce radiation exposure, a quite relevant issue in patients who
need serial examinations for monitoring disease progression,
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FIG. 3. Different CT and chest sonography patterns of absent, intermediate and severe fibrotic involvement.
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FIG. 4. The hypothesized physical and anatomic basis of ULCs. Reflections of the ultrasound beam by thickened interlobular septa give rise to ULCs. Modified from Ref.
[13] with kind permission from the American Journal of Cardiology.
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especially in young women who have a 37% higher cancer risk
than men for any radiation [24]. A reduction of radiation exposure
could also be achieved by low-dose chest CT or chest MRI, which
are, however, more costly and less widely available than chest
sonography [25].
From the scientific viewpoint, ULCs are attractive as a specific,
proximal biomarker of lung fibrosis, of special interest in viewing
the ongoing development of novel methods to prevent scarring
and alleviate the symptoms of fibrosis [26]. A direct, quantitative,
early and radiation-free imaging biomarker would greatly
facilitate the presence of validation of new therapies in this
field [27].
Comparison with previous studies
This is the first study evaluating the presence of a chest sonogra-
phy sign of interstitial fibrosis in patients with SSc, in comparison
with the gold-standard HRCT. Previous studies had evaluated this
sign in different forms of ILD, including pulmonary fibrosis and
sarcoidosis, underlining that diffuse parenchymal lung disease
should be considered in presence of multiple ULCs distributed
over the whole surface of the lung [8]. Because diffuse parenchy-
mal lung disease was defined on the basis of chest X-ray, our study
represents the first quantitative comparison between chest
sonography and radiographic signs of pulmonary fibrosis on
HRCT.
We found higher values of ULCs to be associated to the diffuse
form of the disease, compared with the limited form, and a
correlation between ULC number and values of DLCO. It is estab-
lished that patients with the dcSSc compared with the lcSSc
subgroup have a higher prevalence of interstitial lung fibrosis
documented on HRCT, a reduced lung diffusing capacity [28]
and a significant decrease in the mean percentage of forced vital
capacity and total lung capacity [29].
Chest sonography is more often performed by medium- to low-
frequency transducers, such as convex, micro-convex or cardiac
probes, whereas high frequency linear probes are considered to be
the best tool for visualization and measurement of the pleural line.
We employed cardiac probes, which allow a clear visualization of
ULCs and are very easy to handle along patients’ intercostal
spaces. However, it is likely that similar results would have been
found by using a convex or micro-convex probe [30, 31].
Limitations
Some limitations of the proposed chest ultrasound method should
be acknowledged. A limit of ULCs may arise from the differential
diagnosis between cardiogenic and fibrotic ULCs. Cardiogenic
watery ULCs may be difficult to distinguish from pneumogenic
fibrotic ULCs, which can be typically found in ILD. Usually,
diagnosis is obvious from patient’s history and/or from dynamic,
serial evaluation, since only cardiogenic comets are cleared by
diuretic therapy [7]. However, in the present study only the fibro-
tic origin has been considered as the possible origin of abnormal
signal, given the clinical context. In a less well-selected patient
population, problems of differential diagnosis between fibrotic
and watery ULCs may arise [7].
The sample size was limited and, moreover, only a few patients
had important pulmonary fibrosis and nobody had a very high
Warrick score, potentially influencing ULC accuracy. This was a
pilot study; additional studies, including a higher number of
patients with the whole range of degrees of pulmonary fibrosis,
will be needed to provide more accurate information on sensitivity
and specificity, as well as reproducibility and feasibility for
patients’ follow-up.
As always, the reading of ultrasound was subjective and quali-
tative. Although a semiquantitative index of ULCs was generated,
there is no doubt that quantitative radiological imaging provides
a more established and robust quantitative support to the diag-
nosis of lung fibrosis. It is also unquestionable, however, that a
user-friendly, easy and fast approach of chest sonography may be
appealing in the initial characterization and follow-up of these
patients in a cost- and risk-conscious perspective [32–35].
Rheumatology key messages
 ULCs are well correlated with HRCT signs of pulmonary fibrosis.
 ULCs represent a simple, bedside, radiation-free hallmark of
pulmonary fibrosis.
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